JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO
16.1.2023 12:00:00 EET | Business Wire | Press release
Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.
Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.
“I am delighted that Dr Richard Marshall CBE, the former Senior Vice-President, Global Head of Development, Respiratory & Immunology at AstraZeneca, has agreed to lead Juvenescence as CEO. Throughout his career, Richard has been the architect of numerous transformative R&D strategies to drive innovation and deliver rapid growth, with a track record of collegial success, building high performing teams and developing novel therapies,” outgoing CEO Dr Gregory Bailey said. “Richard is a results-oriented leader who believes that in a post-COVID-19 world facing the impending crisis of an inverted demographic pyramid coupled with undercapitalized pension funds and ever-increasing healthcare costs, proactive, decentralized solutions are desperately needed. Juvenescence is a critical player in the mega-trends now driving towards the healthier lifestyles and digital health strategies needed to confront these issues. I am confident that with this appointment, we have a world class team with the experience and skillset to position Juvenescence as one of the premier biotech and pharmaceutical companies focused on modifying aging through prevention.”
Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”
About Juvenescence
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan. It was founded by Jim Mellon, Dr Greg Bailey and Dr Declan Doogan. The Juvenescence team consists of highly experienced drug developers, entrepreneurs, marketers, and investors with a significant history of success in pharmaceutical drug development, synthetic biology, and tissue and cellular engineering.
Juvenescence has a broad portfolio of products in development and is driving innovation, with a focus on discovering and developing these therapies to modify the aging process, through prevention and by regenerating damage, to support healthy aging and increase health span. The company is committed to inspiring and equipping the world to, not just reimagine what it means to age, but to help people Reimagine A Lifetime. For more information see: www.JuvLabs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230116005022/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health11.3.2026 11:00:00 EET | Press release
Haleon, a consumer company that is solely focused on better everyday health, is investing £65 million in a new state-of-the-art oral health manufacturing site in Shanghai. The facility will support the expansion of its oral care portfolio – which includes the global brands Sensodyne and parodontax – into China’s fast-growing tier 2 and tier 3 cities, where rising incomes, growing awareness of everyday health and a shift towards trusted, branded products are reshaping consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311389622/en/ parodontax, Haleon's clinically proven gum health brand, is expanding across China As part of this shift, more consumers are embedding preventative oral care into their daily self-care routines, and demand for premium, science-backed solutions is accelerating at a rapid pace. This investment strengthens Haleon’s local manufacturing footprint and positions the business to capture
Eurofins Biomnis Launches New Clinical LC‑MS/MS Method for the Detection of Cereulide Toxin in Stool Samples11.3.2026 10:00:00 EET | Press release
Eurofins Biomnis, a leading European provider of specialised clinical diagnostics services, and part of the global network of Eurofins laboratories, announces the successful development and validation of a new liquid chromatography tandem mass spectrometry (LC‑MS/MS) method for the detection and quantification of cereulide toxin in human stool samples. This innovation underlines Eurofins Biomnis’ diagnostic innovation, and its commitment to contributing its expertise to reducing diagnostic uncertainty with solutions that support clinicians and laboratories nationwide and internationally. Eurofins Biomnis has fully validated the method for human stool samples, taking into account matrix effects and meeting the requirements of ISO 15189 (with the exception of inter‑method comparison on pathological clinical samples). Cereulide, a toxin produced by specific strains of Bacillus cereus, has recently raised significant public attention following contamination events involving infant formula
1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage11.3.2026 09:40:00 EET | Press release
1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform. The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two biggest massive IoT network specialists — 1NCE, the biggest private IoT network in the cloud and Netmore, the largest LoRaWAN network and platform provider in the world. 1NCE’s software and connectivity platform has become a new industry standard. Working together to support their respective customer bases with both cellular and LoRaWAN technology delivers a powerful layer of redundancy to cover the hardest to re
1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage11.3.2026 09:40:00 EET | Press release
1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform. The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two biggest massive IoT network specialists — 1NCE, the biggest private IoT network in the cloud and Netmore, the largest LoRaWAN network and platform provider in the world. 1NCE’s software and connectivity platform has become a new industry standard. Working together to support their respective customer bases with both cellular and LoRaWAN technology delivers a powerful layer of redundancy to cover the hardest to re
Codethink Opens Early Access to IEC 61508 Mapping for the Eclipse Trustable Software Framework11.3.2026 09:07:00 EET | Press release
EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of electrical and electronic systems. The mapping establishes a transparent relationship between the engineering principles of the Trustable Software Framework and the objectives defined in IEC 61508. By making this work available as an early preview, Codethink is inviting organisations interested in applying open source approaches to functional safety to review and begin working with the mapping while the work continues to mature. IEC 61508 forms the foundation of many domain-specific safety standards, including ISO 26262 for automotive systems. The early access reflects Codethink’s long-standing commitment to open development of software engineering methods. “This preview release reflects our belief that trust in software must be engineered in the open," said Paul Sherwood, Codethink’s Chair
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom